Park Jae-Don – Chairman, Korea Pharma
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Korea Pharma Co. Ltd (KP) has sought to help people keep and improve their health for more than 30 years, based on the principles of “respect for human life and dignity.” With fully validated cGMP facility and a strong quality control system, KP’s products are safe, stable, and of high quality and efficacy. At present, KP is seeking to achieve a healthier future for the 21st century by concentrating on the constant research and development of various kinds of pharmaceutical products.
KP also manufactures products for multinational companies such as Mundi Pharma and Stiefel, developing high quality preparations using advanced Drug Delivery Systems. In all, KP exports more than 40 kinds of products to over 16 countries.
Contact Details
87 Jeyakgongdan 3-gil, Hyangnam-eup, Hwaseong-si, Gyeonggi-do
Korea (135-060)
Tel; +82-2-558-1277
webmaster@koreapharma.co.kr
The chairman of contract manufacturer Korea Pharma discusses the Korean CMO market and incremental innovation. Where did your idea for starting Korea Pharma come from? I am a pharmacist…
Could you please introduce KPMA and explain the role it plays within the South Korean pharmaceutical industry? KPMA is the only association in South Korea regrouping the whole range of…
Dr Kyung Sook Kim, CEO of Corestem, explains how her company has been pioneering the Korean stem cell industry since its foundation in 2003. She also discusses reimbursement and regulation…
Dr Jino Park, founder and CEO of P&K Skin Research Centre, offers his assessment of the success of the Korean pharmaceutical industry, and the potential cosmetic products of the future.…
Ji-Young Lee, senior director clinical operations, and general management & business administration Korea of PAREXEL Korea discusses the strengths of Korea’s clinical research environment, and how PAREXEL can leverage its…
* This interview was conducted before GE’s announcement of its divestment of the GE Biopharma business Francis Van Parys, president & CEO of GE Healthcare Korea discusses their ambitions to…
Young Kim, founder and CEO of Synex Consulting Ltd., a consulting firm assisting healthcare companies in introducing and marketing their products on the Korean market, discusses how Synex’s ICC (In-Country…
Min-Young Kim, general manager at Ipsen Korea discusses her strategy to refocus the Korean affiliate away from the toxin market and towards oncology and rare diseases. She also documents Ipsen’s…
Woosok Lee, CEO of Kolon Pharma, Kolon Life Science and Kolon TissueGene, offers his insights into the potential of their blockbuster product Invossa which could exceed USD five billion of…
Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision…
Professor Dae Ho Lee has been researching and treating Korean cancer patients for more than 20 years and advises the current government on healthcare policy. He breaks down the benefits…
This week the Korean Ministry of Food and Drug Safety announced that as of 12th March 2019 a revised narcotics bill will go into effect that will allow imports of medical…
Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a…
YJ Kim, country manager at BD Korea, discusses the integration of Bard into BD at the local level. He also offers his insights into the challenges of approval and pricing…
See our Cookie Privacy Policy Here
